James Allison studies the regulation of T cell responses. He identified CTLA-4 as a molecule that acts to limit T cell responses. He was the first to propose that blockade of the inhibitory signals mediated by CTLA-4 could enhance T cell responses to achieve tumor eradication. He conducted the preclinical work with a CTLA-4 targeted antibody that led to its clinical development and eventual approval as a standard of care therapy for the treatment of patients with melanoma. He is now focused on developing novel combination strategies of immune checkpoint blockade to enhance efficacy and broaden application of this strategy for cancer therapy.
« Go Back